Ischemic optic neuropathy
Conditions
Interventions
Intervention group 1:Simple ultrasound (high mechanical index, MI)
Intervention group 2:Diagnostic ultrasound combined with microbubble (high mechanical index)
Intervention group 3:Diagnostic ultrasound combined with microbubble (low mechanical index,)
Sponsors
The Second Affiliated Hospital of Army Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Over 18 years old; 2. Consistent with clinical manifestations of ischemic optic neuropathy, such as sudden painless vision loss accompanied by positive RAPD, excluding other ocular nervous system diseases or systemic diseases; The clinical diagnosis was papilledema, which was confirmed by optic disc OCT. The edema of optic disc subsided within 2 months, and optic nerve atrophy was formed. 3, Consistent with the clinical manifestations of central retinal artery occlusion, such as sudden unilateral painless sharp visual loss, accompanied by ipsilateral relative afferent pupillary dysfunction (+). The typical manifestations of fundus examination are gray, edema, and relative red macula in the posterior pole retina (i.e. "cherry erythema"), and FFA may indicate slow segmental decreased blood flow in the retinal artery. 4. Consistent with the clinical manifestations of retinal vein occlusion and FFA suggested retinal vein occlusion, sudden and painless visual loss in one eye. The typical manifestations of fundus examination were tortuosity and dilation of the involved retinal vein around the occlusion site, as well as internal retinal hemorrhage and macular edema. 5. Patients who meet the diagnosis of optic atrophy; 6. Willing to participate in this study and sign informed consent.
Exclusion criteria
Exclusion criteria: 1. Suffering from glaucoma or any other eye disease, neurological or systemic disease, etc., which may affect vision and visual field; 2. Exclude arteritis, such as erythrocyte sedimentation rate greater than 50mm/h, C-reactive protein greater than twice the normal value; Diseases related to abnormal immune function, such as lupus erythematosus, Sjogren's syndrome, etc. 3. Optic neuropathy after cataract surgery or caused by blood loss; 4. Recent (1 month) history of corneal surgery, retinal exfoliation, silicone oil filling or other intraocular surgery, and ocular erythema and pain; 5. Took other experimental drugs or participated in other clinical trials 3 months before study inclusion; 6. Patients who are allergic to contrast media and cannot undergo contrast-enhanced ultrasound; 7. For any reason, it is not suitable to cooperate with the study or the researcher thinks it is not suitable to be included in this experiment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Vision; | — |
Secondary
| Measure | Time frame |
|---|---|
| Visual field;RNFL-TO;Tthickness from the ILM line to the IPL line;Fundus photography;Arm-to-retina time;Arterial phase;Peak systolic velocity of the central retinal artery;End-diastolic velocity of the central retinal artery;Peak systolic velocity of the central retinal vein;Peak systolic velocity of the posterior ciliary artery;End-diastolic velocity of the posterior ciliary artery;Peak systolic velocity of the arteriae ophthalmosa;End-diastolic velocity of the arteriae ophthalmosa;Resistance index of the central retinal artery;Resistance index of the posterior ciliary artery;Resistance index of the arteriae ophthalmosa;Super microvascular imaging observation;Time to peak;Maximum intensity;Rising time;Mean transit time;Area under the curve; | — |
Countries
China
Contacts
Public ContactPeijing Li
The Second Affiliated Hospital of Army Medical University
Outcome results
None listed